Results 51 to 60 of about 220,141 (335)

Antipsychotic drug-induced neutropenia: results from the AMSP drug surveillance program between 1993 and 2016 [PDF]

, 2023
Catherine Glocker, R. Grohmann, Gerrit Burkhardt, Johanna Seifert, Stefan Bleich, Thomas Held, Sermin Toto, Susanne Stübner, Cornelius Schüle   +8 more
openalex   +1 more source

Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Belimumab in Pediatric Patients with Systemic Lupus Erythematosus: A Multicenter, Open‐Label Trial

Arthritis Care &Research, Accepted Article.
Objective This study aimed to characterize the pharmacokinetics, pharmacodynamics, safety, and exploratory efficacy of subcutaneous belimumab in pediatric patients with active systemic lupus erythematosus (SLE) receiving standard therapy. Methods This single‐arm, multicenter, open‐label trial (GSK study 200908; NCT04179032) used three‐weight‐band ...
Hermine I. Brunner, Jordi Antón, Inmaculada Calvo‐Penadés, Richard Dimelow, Gerd Horneff, Sylvia Kamphuis, Rebecca Marino, Andre van Maurik, Kirsten Minden, Masaaki Mori, Josephine Ocran‐Appiah, Christel Wilkinson, Yuichi Yamasaki, Deepak Assudani, for the Pediatric Rheumatology Collaborative Study Group (PRCSG) and Paediatric Rheumatology International Trials Organisation (PRINTO) network investigators   +14 more
wiley   +1 more source

Neutropénia transitória na criança previamente saudável.

Acta Médica Portuguesa, 2001
Transient neutropenia in otherwise healthy children is not unusual, the main causes being infections and drugs. The risk of developing an infectious complication in previously healthy children with transient neutropenia is low.
P Martins, H Pedroso, J G Marques
doaj   +1 more source

Host‐Directed Biomaterials for Combatting Bloodstream Infections: From Macrocyclic Peptides to Immune‐Activating Cell Backpacks

Advanced Functional Materials, EarlyView.
Bloodstream infections (BSI) are one of the leading causes of mortality and morbidity in both civilian and military populations. This paper summarizes recent progress in novel treatment strategies to manage BSI arising from both bacterial and fungal pathogens using molecules, particles, and materials to elicit host‐directed immunity.
Thomas Thomou, Jagadish Krishnappa, Justin B. Schaal, Prasad Tongaonkar, Dat Q. Tran, Wenchao Gu, Yung‐Fu Chang, Michael E. Selsted, Shaoyi Jiang, Samir Mitragotri, Michael Super, Christopher J. Bettinger   +11 more
wiley   +1 more source

Mecapegfilgrastim prophylaxis for neutropenia in patients with non-myeloid malignancies: A Chinese nationwide real-world study

BMC Cancer
Background Mecapegfilgrastim has been previously validated for efficacy and safety in neutropenia prevention during clinical trials. This nationwide, real-world study (RWS) evaluates its role in protecting against moderate to severe chemotherapy-induced ...
Shukui Qin, Yanxia Shi, Peifen Fu, Nong Xu, Chenyu Mao, Yong Chen, Yongsheng Wang, Huiqiang Huang, Xin Huang, Yongqing Li, Haijiao Yan, Yumin Yao, Gang Cheng, Zhe Yang, Ningling Zhang, Guifang Zhang, Minbin Chen, Hua Jiang, Zhangxia Ren, Liang Chen, Lifang Ding, Ruihua Xu, Jun Ma   +22 more
doaj   +1 more source

Human Inborn Errors of Immunity: 2019 Update of the IUIS Phenotypical Classification. [PDF]

, 2020
Since 2013, the International Union of Immunological Societies (IUIS) expert committee (EC) on Inborn Errors of Immunity (IEI) has published an updated phenotypic classification of IEI, which accompanies and complements their genotypic classification ...
Ailal, Fatima, Al-Herz, Waleed, Bousfiha, Aziz, Casanova, Jean-Laurent, Chatila, Talal, Cunningham-Rundles, Charlotte, Etzioni, Amos, Franco, Jose Luis, Holland, Steven M, Jeddane, Leila, Klein, Christoph, Morio, Tomohiro, Ochs, Hans D, Oksenhendler, Eric, Picard, Capucine, Puck, Jennifer, Sullivan, Kathleen E, Tangye, Stuart G, Torgerson, Troy R   +18 more
core  

Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. [PDF]

, 2016
Preclinical models suggest that histone deacetylase (HDAC) and mammalian target of rapamycin (mTOR) inhibitors have synergistic anticancer activity. We designed a phase I study to determine the safety, maximum tolerated dose (MTD), recommended phase II ...
Falchook, Gerald S., Fanale, Michelle A., Fu, Siqing, Garrido-Laguna, Ignacio, Hong, David S., Janku, Filip, Kaseb, Ahmed O., Kurzrock, Razelle, Meric-Bernstam, Funda, Naing, Aung, Park, Haeseong, Patel, Shreyaskumar, Piha-Paul, Sarina A., Subbiah, Vivek, Tsimberidou, Apostolia M., Velez-Bravo, Vivianne M M., Wheler, Jennifer J., Zinner, Ralph G.   +17 more
core   +2 more sources

Surgical approach for appendicitis in neutropenia: a case report and review of the literature [PDF]

, 2022
Ushanthan Uthayanan, Walter Kolb, Bruno M. Schmied, Stephan Bischofberger   +3 more
openalex   +1 more source

Three‐Year Follow‐Up of Neoadjuvant Tislelizumab with Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Revealing Cancer‐Associated Fibroblast Heterogeneity Corresponding to PD‐1 Blockade Efficacy

Advanced Science, EarlyView.
Heterogeneous cancer‐associated fibroblasts orchestrate dual immune microenvironments in LAGC. Abstract The potential for immunotherapy in patients with locally advanced gastric cancer (LAGC) is recently confirmed. To report the 3‐year follow‐up data are aimed from a novel clinical trial. This is a prospective single‐arm phase II trial.
Yao Lin, Xiong Sun, Chengguo Li, Ming Yang, Ke Wu, Ke Liu, Anshu Li, Xiaoming Shuai, Kailin Cai, Zheng Wang, Guobin Wang, Peng Zhang, Jianfeng Shen, Kaixiong Tao, Yuping Yin   +14 more
wiley   +1 more source

Impact of Neutropenia on Clinical Outcomes in Critically Ill Patients with Acute Respiratory Failure

Pulmonary Therapy
Introduction Neutropenia is a common clinical condition in critically ill patients and may be associated with poor outcomes, particularly in the context of acute respiratory failure (ARF).
Hwan Il Kim, Seong Mi Moon, Hyo Seok Oh, Ryoung-Eun Ko   +3 more
doaj   +1 more source